Neurovance

Neurovance is led by co-founder Anthony McKinney who is joined by a team of seasoned drug developers. Members of the management team participated in the development of Prozac, Cymbalta, Lunesta, Strattera and Zyprexa—all successful neuroscience medications. Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich. Neurovance is headquartered in Cambridge, Massachusetts.